NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
Clinical Trials
9 trialsNCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT06731894 2025-12-05
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
City of Hope Medical Center
Phase 2 Recruiting
NCT07167446 2025-10-22
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05836857 2025-10-14
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
M.D. Anderson Cancer Center
Active not recruiting
NCT03948074 2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2 Completed
NCT06538389 2025-08-29
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT04482244 2025-07-29
RCT of CBD for Anxiety in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04754399 2025-05-09
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
University of Michigan Rogel Cancer Center
Phase 2 Completed